Clinical trials: Urinary System Tumor
Metastatic Renal Cell Carcinoma
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on…
- Trial name
- NCT00444314
- Testing
- Panzem® NCD, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- CASI pharmaceuticals, Inc.
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal…
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma
- Trial name
- NCT06479811
- Testing
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
MEtatastic Renal Carcinoma LINes
The hypothesis of this study are as follows: Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
- Trial name
- MERLIN (NCT03928964)
- Where
- 8 sites in France
- Volunteers
- 440 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Bladder Cancer
Antitumor T Cell Responses in Patients With Bladder Cancer
The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatments in patients with bladder tumor.
- Trial name
- immunoBLAD (NCT06334406)
- Testing
- Biological samples
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
Immune Checkpoint Inhibitors, Metastatic Solid Tumor
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to…
- Conditions
- Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma
- Trial name
- NCT05863052
- Testing
- Immunotherapy
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Bladder Cancer
Randomized Trial Comparing Robotic and Open Radical Cystectomy
The purpose of this study is to determine if using robotic surgical technology during bladder cancer surgery helps to reduce complications during and after the surgery.
- Trial name
- NCT01076387
- Testing
- open radical cystectomy, robotic-assisted radical cystectomy
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated…
- Trial name
- NCT01577784
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Bladder Carcinoma, Post-operative Pain
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
This randomized phase IV trial studies how well the continuous infusion of ropivacaine hydrochloride works in reducing pain after surgery in patients with bladder cancer.
- Trial name
- NCT02438852
- Testing
- Questionnaire Administration, Ropivacaine Hydrochloride
- Where
- United States
- Sponsor
- University of Southern California
Urinary Bladder Cancer
Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection
To study the feasibility of using magnetic resonance imaging (MRI) in evaluation UB wall thickening after transurethral resection (TUR) of bladder cancer.
- Trial name
- NCT05787938
- Testing
- MRI
- Volunteers
- 58 people
- Sponsor
- Assiut University
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft…
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03071328
- Testing
- Isovue-M 200
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Renal Cell Carcinoma
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC.
- Trial name
- NCT00557830
- Testing
- Sorafenib Escalated Dose, Sorafenib Standard Dose
- Where
- 13 sites in United States
- Volunteers
- 12 people
- Sponsor
- Accelerated Community Oncology Research Network
Advanced Cancer, Solid Tumors
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies.
- Trial name
- NCT00629200
- Testing
- Sodium Stibogluconate, Interferon Alpha-2b
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Application-based Perioperative Management of the Radical Cystectomy Patient
The purpose of this study is to learn whether it is feasible to use the LifeScience Technologies application (LST app) in patients undergoing radical cystectomy with the eventual goal to reduce complications and readmissions to…
- Trial name
- NCT02942121
- Testing
- LifeScience Technologies application
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Bladder Cancer
Can Four Weeks-check Cystoscopy and Urine Cytology After Primary Complete Resection of T1 Bladder Cancer Replace Repeat Biopsy?
The primary objective of this prospective study is to evaluate the clinical performance of combined check cystoscopy and urine cytology findings 4 weeks after initial primary complete resection of T1 BC for detection of residual…
- Trial name
- NCT05167916
- Testing
- Outpatient check cytoscopy, Urine cytology
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2.
- Trial name
- NCT00009919
- Testing
- semaxanib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal…
- Trial name
- NCT00502034
- Testing
- Interferon Alfa-2a, Interleukin-2
- Where
- 8 sites in Italy
- Volunteers
- 310 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.